Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ZOCOR

« Back to Dashboard
Zocor is a drug marketed by Merck and is included in one NDA. It is available from two suppliers.

The generic ingredient in ZOCOR is simvastatin. There are thirty-six drug master file entries for this compound. Two suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the simvastatin profile page.

Summary for Tradename: ZOCOR

Suppliers / Packagers: see list10

Pharmacology for Tradename: ZOCOR

Clinical Trials for: ZOCOR

Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes
Status: Completed Condition: Type 1 Diabetes Mellitus; Dyslipidemia

A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)
Status: Terminated Condition: Type 2 Diabetes Mellitus

Study of Metformin With Simvastatin for Men With Prostate Carcinoma
Status: Withdrawn Condition: Prostate Carcinoma

Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)
Status: Completed Condition: Cardiovascular Disorder; Diabetes Mellitus

MK0524B Bioequivalence Study (0524B-070)
Status: Completed Condition: Dyslipidemia

Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage
Status: Terminated Condition: Aneurysmal Subarachnoid Hemorrhage; Cerebral Vasospasm

Bioequivalence Study of Simvastatin Tablets, 80 mg of Dr. Reddy's Under Fed Conditions
Status: Completed Condition: Healthy

Bioequivalence Study of Simvastatin Tablets 80 mg of Dr. Reddy's Under Fasting Condition
Status: Completed Condition: Healthy

Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment
Status: Completed Condition: Metabolic Syndrome

Simvastatin (Zocor) Therapy in Sickle Cell Disease
Status: Completed Condition: Sickle Cell Disease

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
TABLET;ORAL019766-001Dec 23, 1991RXNo<disabled><disabled>
TABLET;ORAL019766-004Dec 23, 1991RXNo<disabled><disabled>
TABLET;ORAL019766-002Dec 23, 1991RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn